Cancer Diagnosis by Multiplex Protein Epitope Profiling

Project Information

CANDLE

Grant agreement ID: 697211

DOI

10.3030/697211

Project closed

EC signature date 26 August 2015

Start date 1 September 2015

End date 31 October 2015

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

BIOSYSTEMS INTERNATIONAL KUTATO-, FEJLESZTO-, HASZNOSITO ES SZOLGALTATO KFT
Hungary

Periodic Reporting for period 1 - CANDLE (Cancer Diagnosis by Multiplex Protein Epitope Profiling)

Reporting period: 2015-09-01 to 2015-10-31

Summary of the context and overall objectives of the project

Cancer incidence is continuously increasing, making it a major concern of European governments. Cheaper, more sensitive and specific diagnostic tests are needed to foster early cancer diagnosis, thereby alleviating the impact of cancer on citizens’ lives and reducing overall cancer care costs. Biosystems International Kft. (BSI) developed a diagnostics technology based on plasma protein epitome biomarker panels, with promising results to meet these needs for breast (BC) and colon (CC) cancers. BSI’s novel biomarkers-based in vitro diagnostics will bring better health outcomes for the patient as earlier detection will increase survival and will reduce overall care costs contributing to the sustainability of the health care system.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

In Phase I of CANDLE, BSI consolidated the business plan incorporating thorough market and commercialization studies for BC and CC and conducted a technology intellectual property evaluation. In order to execute the plan in Phase II, BSI recruited the critical experts and stakeholders and obtained expert opinions and intents for the design and development to complete clinical validation of the biomarker panels for BC and CC. The two cancers together represent 26.8 % of all cancer incidences in the EU. Clinically validated results obtained in CANDLE will enable BSI to seize the business opportunity and to maximize return on investments through higher royalties.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

BSI will develop blood tests that could become blockbusters in the BC and CC diagnostic markets. The optimal expected impact of successful early diagnostics (screening) in CC and BC is the reduction of mortality and increase in cancer-free survival. Based on our projections the increase in five-year survival could reach 5-20 % depending on the cancer type.

bsi-graphics.jpg